Paragon 28 Announces the Launch of SMART 28℠ Portal and First Case Using SMART Bun-Yo-Matic℠
2024年8月14日 - 8:00PM
ビジネスワイヤ(英語)
Paragon 28, Inc. (NYSE: FNA), is proud to announce the launch of
the SMART28℠ Case Management Portal, a cutting-edge platform that
leverages AI and a seamless user experience to coordinate
patient-specific surgical plans. It is the first major launch of
Paragon 28’s SMART28℠ ecosystem, a portfolio of solutions and
products that drive Paragon 28’s SMART28℠ initiative: to improve
all aspects of foot and ankle treatments through the utilization of
artificial intelligence, data analytics, patient specific
algorithms, 3D modeling, and other enabling technologies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240814610485/en/
Figure 1: Smart Bun-Yo-Matic Case
Management and Workflow (Graphic: Paragon 28)
The SMART28℠ Case Management Portal gives surgeons the ability
to plan cases, coordinate surgery dates, and submit patient
imaging. It will also serve as a direct line of communication with
the Paragon 28 engineering and sales teams for real-time support,
status updates, and surgical planning insights. The first module to
launch within the Case Management Portal is SMART Bun-Yo-Matic℠ for
bunion correction.
SMART Bun-Yo-Matic℠ has imaging optionality to input either
patient weight-bearing X-rays or weight-bearing CT (“WBCT”) scans.
It is the first foot and ankle orthopedic device on the market that
allows the user to see the foot as 3D anatomy from two X-ray
images. If a surgeon uses WBCT, they have access to “see inside the
joint,” allowing the user to assess the joint distance distribution
specific to their patient and compare it to normal joint
alignment.
SMART Bun-Yo-Matic℠ revolutionizes preoperative planning and
correction for hallux valgus by creating plans tailored to the
individual patient. AI-driven algorithms and statistical shape
modeling integrate with surgeon input, and within 10 minutes,
export a surgical plan for correction, notifying the user if
abnormal anatomy is detected. SMART BYM℠ allows the surgeon to
adjust the plan in real time and exports a new surgical plan
incorporating their recommended changes, if desired. The final
surgical plan provides the surgeon user specific reference points
that allow for additional reproducibility when paired with The
Bun-Yo-Matic Lapidus Clamp, which can be used to identify, measure,
and hold the planned corrections in place during the procedure.
Dr. Cesar De Cesar Netto, surgeon designer and one of the first
users of the SMART Bun-Yo-Matic℠, says of the portal: “The ability
to 3D plan your Hallux Valgus correction is crucial for
understanding this complex deformity and optimizing multiplanar
correction. Even more revolutionary is the capability to apply,
control, and achieve the planned correction with the use of the
Clamp. Precision down to the millimeter matters, the SMART
Bun-Yo-Matic℠ system represents a significant advancement in
improving precision and outcomes in Hallux Valgus surgery.”
Paragon 28’s CEO, Albert DaCosta, commented, “We could not be
more excited about the launch of our SMART 28 Case Management
Portal and SMART Bun-Yo-Matic cleared for weight-bearing CT and
X-ray. This marks a tremendous step forward for Paragon 28 and we
expect it will make a big impact on the future of foot and ankle
surgery. With the SMART Bun-Yo-Matic℠, surgeons are able to
efficiently plan a procedure in 3D and have the ability to
precisely implement the plan with full intraoperative control.”
The SMART28℠ Case Management Portal is a foundational tool for
future modules to span many additional foot and ankle conditions.
With the introduction of SMART Bun-Yo-Matic℠, Paragon 28 has taken
a giant leap forward in paving the way for surgeons to utilize
artificial intelligence to optimize surgical outcomes for their
patients.
For more information regarding the SMART 28℠ ecosystem and
modules please visit: https://smart.paragon28.com/
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward-looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward-looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K/A for the
fiscal year ended December 31, 2023 and its Quarterly Reports on
Form 10-Q, as updated periodically with its other lings with the
SEC. These forward-looking statements are made as of the date of
this press release, and Paragon 28 assumes no obligation to update
the forward-looking statements, or to update the reasons why actual
results could di er from those projected in the forward-looking
statements, except as required by law.
Disclaimer
Dr. Cesar De Cesar Netto may report consulting and royalty fees
from Paragon 28 in connection with the provision of product
development services to Paragon 28.
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240814610485/en/
Investor Contact Matthew Brinkman Senior Vice President,
Strategy and Investor Relations mbrinkman@paragon28.com
Paragon 28 (NYSE:FNA)
過去 株価チャート
から 8 2024 まで 9 2024
Paragon 28 (NYSE:FNA)
過去 株価チャート
から 9 2023 まで 9 2024